Ziyin Wang1, Jian Lu2, Wei Huang1, Zhiyuan Wu1, Ju Gong2, Qingbing Wang1, Qin Liu1, Cangyi Wang2, Yu Zhu3, Xiaoyi Ding4, Zhongmin Wang5,6. 1. Department of Radiology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, 197#, Rui Jin Er Road, Shanghai, 200025, People's Republic of China. 2. Department of Radiology, Ruijin Hospital Luwan Branch, School of Medicine, Shanghai Jiao Tong University, 149#, South Chongqing Road, Shanghai, 200020, People's Republic of China. 3. Department of Radiology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, 197#, Rui Jin Er Road, Shanghai, 200025, People's Republic of China. zy10478@rjh.com.cn. 4. Department of Radiology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, 197#, Rui Jin Er Road, Shanghai, 200025, People's Republic of China. dxy10456@rjh.com.cn. 5. Department of Radiology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, 197#, Rui Jin Er Road, Shanghai, 200025, People's Republic of China. wzm11896@rjh.com.cn. 6. Department of Radiology, Ruijin Hospital Luwan Branch, School of Medicine, Shanghai Jiao Tong University, 149#, South Chongqing Road, Shanghai, 200020, People's Republic of China. wzm11896@rjh.com.cn.
Abstract
BACKGROUND: To evaluate the clinical efficacy and safety of ablating renal cell carcinoma (RCC) by irreversible electroporation (IRE). METHODS: Fifteen patients (19 lesions) with RCC who underwent IRE were retrospectively reviewed. Seven patients had solitary kidneys. Two lesions were located in the renal hilus. One patient had chronic renal insufficiency. Percutaneous biopsy for histopathology was performed. The best puncture path plan was evaluated before CT-guided IRE. The estimated glomerular filtration rate (eGFR) was compared vs baseline at 1-2 months after the ablation. Contrast-enhanced computed tomography imaging changes were evaluated immediately after IRE. Contrast-enhanced computed tomography/magnetic resonance was performed 1 month, 3 months, 6 months, 12 months and every year thereafter. The complications after treatment were also reviewed. RESULTS: The success rate of the procedure was 100%. The median tumor size was 2.4 (IQR 1.3-2.9) cm, with an median score of 6 (IQR 5.5-8) per R.E.N.A.L. criteria (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines). Two cases (3 lesions) were punctured through the liver. In other cases, puncture was performed through the perirenal space. There were no severecomplications in interventional therapy. Transient gross hematuria occurred in 2 patients (centrally located). Self-limiting perinephric hematomas occurred in 1 patient. Needle puncture path metastasis was found in 1 patient 2.5 years after IRE. The subcutaneous metastasis was surgically removed, and there was no evidence of recurrence. There was no significant change in eGFR levels in terms of short- term clinical outcomes (t = 0.348, P = 0.733). At 6 months, all 15 patients with imaging studies available had no evidence of recurrence. At 1 year, 1 patient (1 of 15) was noted to have experienced needle tract metastasis and accepted salvage radiofrequency ablation (RFA) therapy. CONCLUSIONS: IRE appears to be a safe and effective treatment for RCC that may offer a tissue-sparing method and complete ablation as an alternative therapy for RCC.
BACKGROUND: To evaluate the clinical efficacy and safety of ablating renal cell carcinoma (RCC) by irreversible electroporation (IRE). METHODS: Fifteen patients (19 lesions) with RCC who underwent IRE were retrospectively reviewed. Seven patients had solitary kidneys. Two lesions were located in the renal hilus. One patient had chronic renal insufficiency. Percutaneous biopsy for histopathology was performed. The best puncture path plan was evaluated before CT-guided IRE. The estimated glomerular filtration rate (eGFR) was compared vs baseline at 1-2 months after the ablation. Contrast-enhanced computed tomography imaging changes were evaluated immediately after IRE. Contrast-enhanced computed tomography/magnetic resonance was performed 1 month, 3 months, 6 months, 12 months and every year thereafter. The complications after treatment were also reviewed. RESULTS: The success rate of the procedure was 100%. The median tumor size was 2.4 (IQR 1.3-2.9) cm, with an median score of 6 (IQR 5.5-8) per R.E.N.A.L. criteria (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines). Two cases (3 lesions) were punctured through the liver. In other cases, puncture was performed through the perirenal space. There were no severecomplications in interventional therapy. Transient gross hematuria occurred in 2 patients (centrally located). Self-limiting perinephric hematomas occurred in 1 patient. Needle puncture path metastasis was found in 1 patient 2.5 years after IRE. The subcutaneous metastasis was surgically removed, and there was no evidence of recurrence. There was no significant change in eGFR levels in terms of short- term clinical outcomes (t = 0.348, P = 0.733). At 6 months, all 15 patients with imaging studies available had no evidence of recurrence. At 1 year, 1 patient (1 of 15) was noted to have experienced needle tract metastasis and accepted salvage radiofrequency ablation (RFA) therapy. CONCLUSIONS: IRE appears to be a safe and effective treatment for RCC that may offer a tissue-sparing method and complete ablation as an alternative therapy for RCC.
Authors: Johann J Wendler; Maciej Pech; Frank Fischbach; Julian Jürgens; Björn Friebe; Daniel Baumunk; Markus Porsch; Simon Blaschke; Daniel Schindele; Sandra Siedentopf; Jens Ricke; Martin Schostak; Jens Köllermann; Uwe B Liehr Journal: Urology Date: 2018-01-02 Impact factor: 2.649
Authors: Jing Wu; Joshua Chang; Harrison X Bai; Chang Su; Paul J Zhang; Giorgos Karakousis; Shilpa Reddy; Stephen Hunt; Michael C Soulen; S William Stavropoulos; Zishu Zhang Journal: J Vasc Interv Radiol Date: 2019-06-05 Impact factor: 3.464
Authors: D K Filippiadis; C Binkert; O Pellerin; R T Hoffmann; A Krajina; P L Pereira Journal: Cardiovasc Intervent Radiol Date: 2017-06-05 Impact factor: 2.740
Authors: Richard L Haddad; Manish I Patel; Philip Vladica; Wassim Kassouf; Frank Bladou; Maurice Anidjar Journal: Urol J Date: 2012 Impact factor: 1.510
Authors: Timothy J O'Brien; Melvin F Lorenzo; Yajun Zhao; Robert E Neal Ii; John L Robertson; S Nahum Goldberg; Rafael V Davalos Journal: Int J Hyperthermia Date: 2019 Impact factor: 3.914
Authors: Kim A Maciolek; E Jason Abel; Natasza M Posielski; J Louis Hinshaw; Meghan G Lubner; Fred T Lee; Timothy J Ziemlewicz; Shane A Wells Journal: Eur Radiol Date: 2019-04-23 Impact factor: 5.315
Authors: Ryan M Hegg; Grant D Schmit; A Nicholas Kurup; Adam J Weisbrod; Stephen A Boorjian; Thomas D Atwell Journal: Cardiovasc Intervent Radiol Date: 2013-08-09 Impact factor: 2.740